Guggenheim, TD Cowen, UBS raise Acadia Healthcare price targets
Guggenheim analyst Jason Cassorla maintained a Buy rating on Acadia Healthcare Co and raised the price target to $38 from $31, joining TD Cowen and UBS who also increased their targets to $36 and $39 respectively. The revisions reflect a positive outlook on the company's valuation and operational strength. Acadia operates 275 facilities across 40 states and Puerto Rico.
*this image is generated using AI for illustrative purposes only.
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) has seen its price target raised by multiple analysts, reflecting an increased valuation outlook for the behavioral healthcare provider. Guggenheim analyst Jason Cassorla maintained a Buy rating on Acadia Healthcare Co and raised the price target from $31 to $38. This follows similar actions by TD Cowen and UBS, who also revised their targets upward, signaling confidence in the company's future performance and operational strength.
Analyst Outlook
TD Cowen analyst Ryan Langston maintains Acadia Healthcare Co with a Buy rating and raised the price target from $30 to $36. Separately, UBS analyst A.J. Rice has maintained a Buy rating on Acadia Healthcare Co and raised the price target to $39 from $31. The revised targets reflect an increased valuation outlook for the healthcare services provider.
| Firm | Analyst | Rating | Previous Price Target | New Price Target |
|---|---|---|---|---|
| TD Cowen | Ryan Langston | Buy | $30 | $36 |
| UBS | A.J. Rice | Buy | $31 | $39 |
| Guggenheim | Jason Cassorla | Buy | $31 | $38 |
The rating upgrades come as firms evaluate Acadia's current market position and growth trajectory. By raising the price targets, TD Cowen, UBS, and Guggenheim indicate potential upside from the previous valuation levels.
Company Overview
As of March 31, 2026, Acadia operated a network of 275 behavioral healthcare facilities with approximately 12,400 beds across 40 states and Puerto Rico. The company employs approximately 25,000 people and serves more than 84,000 patients daily, positioning it as the largest stand-alone behavioral healthcare company in the U.S.
What specific operational metrics or growth drivers are analysts citing to justify the increased valuation outlook?
How might Acadia's expansion strategy evolve given its current position as the largest stand-alone behavioral healthcare provider?
What potential risks or challenges could Acadia face in sustaining the projected growth trajectory?
18
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
